Abstract:Background: Ventricular septal defect (VSD) is the most common congenital cardiac malformation, accounting for approximately 30% of congenital heart defects. Conventional surgical repair using cardiopulmonary bypass is invasive and associated with morbidities and prolonged hospital stay. With the advent of interventional approaches and availability of different occluding devices, the technique of perventricular device closure is evolving and being implemented successfully in larger groups of patients. We present herein, our initial experience of perventricular device closure for the ventricular septal defects in children to assess risks and benefits. Methods: From March, 2023 to February, 2024, we have performed perventricular closure of ventricular septal defects in 13 children, under guidance of transesophageal echocardiography without cardiopulmonary bypass support. The median age at operation was 2 year (range 1.3-10 years) with the median body weight 11 kg (range 8.7-16.6 kg). Sixty-nine percent were males. The ventricular septal defect sizes ranged from 2.7 to 6 mm (mean 4.7 mm). Seven defects were perimembranous, four sub-aortic and two were muscular. One patient also underwent pulmonary artery de-banding with pulmonary artery balloon angioplasty and other one patent ductus arteriosus ligation, concomitantly. For defect closure, we used ventricular septal defect occlusion device (MemoPart™, Lepu Medical Technology Company, China) through a 3-cm skin incision in the lower- third of the sternum. The device sizes ranged from 5 to 8 mm (mean 6.9+-1.8 mm) and all patients except for two required symmetrical devices. Results: All patients underwent device closure successfully. The procedural duration ranged between 32 and 52 min. None of the patients required cardiopulmonary bypass. The mean ventilation time and intensive care unit stay was 3 and 24 h, respectively. None of the patients required inotropic support or blood transfusions. Moreover, no patients developed any arrhythmias including heart block. The average length of hospital stay was 4.4 days. At the latest follow up, there were no residual shunts, conduction disturbances, device dislodgement or major aortic or tricuspid valve complications seen in any patients. There was no mortality. Conclusions: Perventricular device closure of ventricular septal defects is a less invasive, extremely safe and effective method in children. It is associated with very fast recovery, shorter hospitalization time and better cosmetic incision. Moreover, it avoids cardiopulmonary bypass. The modifications and refinements in the design, material and implantation techniques will help in expanding the indications and prevent complications in the long-term.

Device closure of residual aortopulmonary window using Konar-MF occluder device: an attractive new option

Transcatheter closure of a large aortopulmonary window using a LifetechTM Konar-MF occluder device

Transcatheter occlusion of patent ductus ateriosus by Rashkind occluder system

Percutaneous closure of restrictive‐type perimembranous ventricular septal defect using the new KONAR multifunctional occluder: Midterm outcomes of the first middle‐eastern experience

Clinical Observation of Modified Implantation of ASD Closure Device to Treat BPFs

Clinical Application of Minimal Invasive Closure of Atrial Septal Defect Without Cardiopulmonary Bypass

Transcatheter Closure of Secundum Atrial Septal Defect with Amplatzer Occluder Device

Perimembranous Ventricular Septal Defect with Aneurysm Two Options for Transcatheter Closure

Procedural outcomes of percutaneous closure of perimembranous and other ventricular septal defects using Konar-MF occluder and short-term follow-up

Interventional Occlusion of Congenital Vascular Malformations.

Late complete atrioventricular block after transcatheter perimembranous ventricular septal defect closure with the KONAR-MFTM VSD occluder: a case report and systematic review

Initial Experience With an Amplatzer Cribriform Occluder in Patients With Atrial Septal Defects in Pakistan

Word of caution: silent late device embolisation after perimembranous ventricular septal defect closure in a 6-Kg infant

Perventricular device closure of the ventricular septal defects in children-first experience in the United Arab Emirates

Innovative Method for Amplatzer Device Implantation in Patients with Bronchopleural Fistulas.

Closure of small fenestrations without optimal rims with a PDA coil far from primary atrial septal defects: a new approach

Recent developments in next-generation occlusion devices

Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: Initial clinical experience

Recent Development of Biodegradable Occlusion Devices for Intra-Atrial Shunts

Experimental study of the bilateral asymmetric single-rivet occluder device for transcatheter patent foramen ovale closure with reserved interatrial septal puncture area

Transcatheter closure of perimembranous ventricular septal defect using amplatzer ductal occluder